Jubilant Life Sciences, an integrated global Pharmaceuticals and life sciences company, has received abbreviated new drug application (ANDA) final approval from the US Food and Drug Administration  (USFDA)  for  Indomethacin ER capsule 75mg.

Indomethacin ER capsule is a  non-steriodal anti-inflammatory drug used for treatment of pain. 

As on Jun. 30, 2015, Jubilant Life Sciences had a total of 815 filings for formulations of which 389 have been approved in various regions globally.

This includes 72 ANDAs filed in the US, of which 38 have been approved and 46 dossier filings in Europe.

Shares of the company gained Rs 8.35, or 2.11%, to trade at Rs 405.00 at the BSE (11.02 a.m., Wednesday).